NCT04443088 2026-03-18
KEYNOTE-E12
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1 Recruiting
Clinical Trials
1,069 trialsNCT05719558 2026-03-18
A Study of ASP1002 in Adults for Treatment of Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT07226180 2026-03-18
Development and Application of Patient-Derived Models of Cancer
Certis Oncology Solutions, Inc
Enrolling by invitation
NCT04958239 2026-03-17
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT06150157 2026-03-16
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06997029 2026-03-16
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT07030712 2026-03-16
MK-8294-001
Merck Sharp & Dohme LLC
Phase 1 Recruiting
NCT05862285 2026-03-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT06178614 2026-03-13
A Study of JNJ-87890387 for Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06941272 2026-03-13
MK-9999-01C
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT02908906 2026-03-12
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT05993299 2026-03-11
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT06902545 2026-03-11
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Astellas Pharma Inc
Recruiting
NCT06340815 2026-03-06
Varian ProBeam Proton Therapy System Clinical Trial (Shandong)
Varian, a Siemens Healthineers Company
Phase NA Completed
NCT06555744 2026-03-06
A Study of ZW191 in Participants With Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT06564233 2026-03-06
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
Friendi.fi Corporation
Phase NA Recruiting
NCT06979596 2026-03-06
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT05376891 2026-03-05
Met Non Small Cell Cancer Registry (MOMENT)
EMD Serono
Recruiting
NCT05611632 2026-03-05
NHS-Galleri
GRAIL, Inc.
Phase NA Active not recruiting
NCT03435796 2026-03-04
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Celgene
Phase 2/3 Recruiting
NCT06713369 2026-03-04
AZD5305
AstraZeneca
Phase 1 Recruiting
NCT03391778 2026-03-03
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
USWM, LLC (dba US WorldMeds)
Phase 1 Recruiting
NCT07046559 2026-03-03
A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY4066708 in Healthy Participants
Eli Lilly and Company
Phase 1 Recruiting
NCT05382559 2026-03-02
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
Phase 1 Recruiting
NCT06014658 2026-03-02
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
MBrace Therapeutics
Phase 1/2 Recruiting
NCT06884618 2026-03-02
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
Hoffmann-La Roche
Phase 1 Recruiting
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT05377554 2026-02-27
Bevonescein for Intra-Operative Nerve Visualization in Head and Neck Surgery
Alume Biosciences, Inc.
Phase 3 Completed
NCT06056791 2026-02-27
CaRe
Inmune Bio, Inc.
Phase 1/2 Completed
NCT06759649 2026-02-27
A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies
Compugen Ltd
Phase 1 Recruiting
NCT07276373 2026-02-27
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
Corcept Therapeutics
Phase 1/2 Recruiting
NCT07438782 2026-02-27
First Time in Human (FTIH) Study to Investigate the Safety and Preliminary Activity of GSK5533524 Alone or in Combination in Adult Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Not yet recruiting
NCT06703346 2026-02-25
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT07156136 2026-02-25
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Immunocore Ltd
Phase 1 Recruiting
NCT06207032 2026-02-24
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
Tempus AI
Recruiting
NCT05303532 2026-02-23
ROSY-D
AstraZeneca
Phase 3 Enrolling by invitation
NCT06959706 2026-02-20
Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors
Tagworks Pharmaceuticals BV
Phase 1 Recruiting
NCT06818643 2026-02-19
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03964233 2026-02-18
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
Boehringer Ingelheim
Phase 1 Completed
NCT06676436 2026-02-18
REALNESS
AstraZeneca
Completed
NCT06311578 2026-02-13
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Johnson & Johnson Enterprise Innovation Inc.
Phase 1 Recruiting
NCT04078295 2026-02-10
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT05673018 2026-02-10
Galleri® in the Medicare Population.
GRAIL, Inc.
Phase NA Recruiting
NCT06607939 2026-02-10
OR2-01
Orionis Biosciences Inc
Phase 1 Recruiting
NCT06634849 2026-02-10
An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).
Pathios Therapeutics Pty Ltd
Phase 1/2 Recruiting
NCT06701201 2026-02-10
A Long-Term Follow-Up Basket Study for Participants Treated With SynKIR Chimeric Antigen Receptor (CAR) T Cell Product
Verismo Therapeutics
Enrolling by invitation
NCT07258836 2026-02-10
A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer
Eli Lilly and Company
Phase 1 Recruiting
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT06593522 2026-02-05
A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
Amgen
Phase 2 Recruiting